SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled 17,604 adults with established CV disease and overweight or obesity, without diabetes. Over a median 39.8 months, semaglutide 2.4 mg reduced MACE (CV death, non-fatal MI, non-fatal stroke) by 20% vs placebo (HR 0.80). First weight-loss drug with established CV benefit in non-diabetic patients. NEJM 2023.
Drugs in this category
Related terms
- Semaglutide
- GLP-1 receptor agonist; active ingredient in Wegovy, Ozempic, and Rybelsus.